These results suggest that PKC overactivity could hinder the NO/cGMP pathway and contribute to the reduced efficacy of PDE5 inhibitors in causing penile vascular relaxation in diabetes, providing a rationale for PKC inhibition as a potential pharmacological strategy for potentiating the efficacy of PDE5 inhibitors in relieving ED in diabetes. This evidence concerns the gene PRRT2 and diabetes mellitus.